U.S. markets close in 6 hours 30 minutes
  • S&P 500

    4,130.68
    -49.08 (-1.17%)
     
  • Dow 30

    33,918.04
    -135.90 (-0.40%)
     
  • Nasdaq

    12,200.82
    +384.50 (+3.25%)
     
  • Russell 2000

    2,001.22
    +40.41 (+2.06%)
     
  • Crude Oil

    76.03
    +0.15 (+0.20%)
     
  • Gold

    1,891.10
    -39.70 (-2.06%)
     
  • Silver

    22.69
    -0.92 (-3.92%)
     
  • EUR/USD

    1.0852
    -0.0059 (-0.54%)
     
  • 10-Yr Bond

    3.5170
    +0.1210 (+3.56%)
     
  • GBP/USD

    1.2116
    -0.0113 (-0.92%)
     
  • USD/JPY

    130.3820
    +1.7780 (+1.38%)
     
  • BTC-USD

    23,318.89
    -569.33 (-2.38%)
     
  • CMC Crypto 200

    532.38
    -4.48 (-0.83%)
     
  • FTSE 100

    7,860.09
    +39.93 (+0.51%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab

Biogen shares jump 4.7% premarket on hopes for its Alzheimer's treatment lecanemab

Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer's disease failed to meet its main goal. German-listed shares of MorphoSys fell 30% on the news, while Roche was down 4% in Zurich as the company said Phase 3 studies evaluating gantenerumab in people with mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia did not meet their primary endpoint of slowing clinical decline. Biogen, which las